Navigation Links
Nektar Therapeutics Announces Second Quarter 2008 Results
Date:8/6/2008

,727) (4,264)

Increase (decrease) in accrued

compensation (3,676) 954

Increase (decrease) in accrued

expenses to contract manufacturers (40,444) -

Increase (decrease) in accrued

expenses 9,099 (1,600)

Increase (decrease) in interest

payable 7 (708)

Increase (decrease) in deferred

revenue (5,321) 16,952

Increase (decrease) in other

liabilities (1,222) (380)

Net cash used in operating activities (96,425) (14,687)

Cash flows from investing activities:

Purchases of investments (334,685) (273,540)

Maturities of investments 369,337 353,171

Sales of investments 28,590 -

Purchases of property and equipment (10,349) (11,765)

Net cash provided by investing

activities 52,893 67,866

Cash flows used in financing

activities:

Proceeds from issuance of common

stock 383 2,708

Payments of loan and capital lease

obligations (1,151) (823)

Repayments of convertible

subordinated notes - (36,026)

Net cash used in financing activities (768) (34,141)

Effect of exchange rates on cash and

cash equivalents (164) 58

Net increase (decrease) in cash and

cash equivalents $(44,464) $19,096

Cash and cash equivalents at

beginning of period $76,293 $63,760

Cash and cash equivalents at end of

period $31,829 $82,856


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
2. Nektar Therapeutics Announces First Quarter 2008 Results
3. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
4. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
5. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
7. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
8. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
9. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
10. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
11. InteKrin Therapeutics Announces $20 Million Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... College, PA (PRWEB) June 18, 2013 ... months, produces increased fluid retention through the tip allowing ... using the Salimetrics Infant Swab (SIS) can ... IL-1beta and Chromogranin A. , The diameter of the ... This allows the new swab to access more saliva ...
(Date:6/17/2013)... New York, NY (PRWEB) June 17, 2013 ... represents the victims of child sexual abuse and their co-counsel, ... child sexual abuse lawsuit the firms filed on ... a Brooklyn Supreme Court Referee on Wednesday awarded $3.5 million ... by his cousin. Following the Referee’s finding in his ...
(Date:6/17/2013)... AZ (PRWEB) June 17, 2013 Vince Del Monte ... Max program they released last year and it will only be ... exclusive 4 day sale Ryan Davids has released an updated Hypertrophy ... can access the Hypertrophy Max review here . , Davids ... some major bonuses during this 4 day sale as an extra ...
(Date:6/17/2013)... distribution of white matter brain abnormalities in some patients ... found in early Alzheimer,s dementia, according to a new ... , "Findings of MTBI bear a striking resemblance ... study,s lead author, Saeed Fakhran, M.D., assistant professor of ... of Pittsburgh School of Medicine. "Additional research may help ...
(Date:6/17/2013)... (PRWEB) June 17, 2013 Daily Gossip ... therefore, publish a thorough review of the Tinnitus ... Daily Gossip presents the natural treatment that ... patients who have tested it. , Based on the ... natural Tinnitus treatment suggested by Thomas Coleman ...
Breaking Medicine News(10 mins):Health News:Salimetrics Redesigns Infant Swab for Faster, Easier Collection 2Health News:Child Sexual Abuse Lawsuit Victim Awarded $3.5 Million by Brooklyn Supreme Court Referee, Plaintiff Represented by Alonso Krangle LLP 2Health News:Child Sexual Abuse Lawsuit Victim Awarded $3.5 Million by Brooklyn Supreme Court Referee, Plaintiff Represented by Alonso Krangle LLP 3Health News:Updated Hypertrophy Max Review Released for Vince Del Monte and Ben Pakulski's Hypertrophy Max Training Program 2Health News:Concussion patients show Alzheimer's-like brain abnormalities 2Health News:Concussion patients show Alzheimer's-like brain abnormalities 3Health News:Thomas Coleman's Tinnitus Miracle Treatment Review Discloses Alternative Natural Cure 2
... (WASHINGTON, July 1, 2010) Older patients with Hodgkin ... high risk of hospitalization for cardiac complications after completing treatment, ... the journal of the American Society of Hematology. HL is ... and approximately 8,500 people were diagnosed with the disease in ...
... of online information about the most common sports medicine diagnoses ... 2010 issue of the Journal of Bone and Joint ... help make medical decisions need to know that the web ... that we decided to undertake this study is that patients ...
... , ... Living Website known for their guides to green living have launched their most recent guides ... , ... Growandmake.com the online Guide to Sustainable Living has just released four new lifestyle guides to ...
... ... line of pure, certified organic essential oils. , ... Fargo, ND (Vocus) July 1, 2010-- Aromatherapy isn’t new to the field ... for multiple reasons. From the Greeks to the Romans to modern day, essential oils have ...
... ... to Conventional Medical Treatments. , ... Boca Raton, FL (PRWEB) July 2, 2010 -- Amy, a 55 year-old ... traditional drug treatment, which included five daily pills and injections, Amy,s condition only worsened, ...
... ... clients and brokers on June 23- 24, 2010 near the home office in Irving, Texas. ... National Healthcare Reform and Trends.” The topics covered developments in healthcare reform and factors influencing ... (PRWEB) July ...
Cached Medicine News:Health News:Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalization 2Health News:Consulting 'Dr. Google' 2Health News:Consulting 'Dr. Google' 3Health News:Growandmake.com Launches New Sustainable Living Guides 2Health News:Certified Organic Aromatherapy Oils Available from Swanson Health Products 2Health News:New Approach to Rheumatoid Arthritis 2Health News:New Approach to Rheumatoid Arthritis 3Health News:HealthSmart Hosts First Forum on National Healthcare Reform and Trends 2
(Date:6/17/2013)... June 17, 2013 Breezy , ... their first product this week using a platform technology enabling ... combats halitosis (bad breath) is being sold in major Israeli ... This commercial launch in Israel follows ... and Spain earlier this year, with ...
(Date:6/17/2013)... N.J. , June 17, 2013 ... announced today a definitive agreement to acquire Aragon ... company focused on drugs to treat hormonally-driven cancers. ... receptor antagonist program.  Aragon,s lead product candidate is ... in Phase 2 development for castration resistant prostate ...
(Date:6/17/2013)... Calif. , June 17, 2013  Imprimis ... announced it has completed the acquisition of intellectual ... from the compounding pharmacy operations of ... allows Imprimis to pursue the commercial development of ... a right of first refusal on additional Buderer ...
Breaking Medicine Technology:A Big "LIKE" for Oral Hygiene 2Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc. 2Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc. 3Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 2Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 3Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 4Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 5
... 26, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... medical devices worldwide, today announced that it will report its ... after the U.S. market closes on May 9, 2011. Mindray,s ... on May 10, 2011 U.S. Eastern Time (8:00 PM on ...
... 2011 Protect Pharmaceutical Corporation (OTCBB: PRTT) today announced ... Officer Ramesha Sesha as its Chief Executive Officer and ... Protect as the Chief Operating Officer and Board Member ... Nectid Inc where he was the Founder and CEO. ...
Cached Medicine Technology:Mindray to Report First Quarter 2011 Financial Results on May 9, 2011 2Protect Pharmaceutical Corporation Appoints Chief Executive Officer and Chief Financial Officer 2
Forte Guide Wire w/Markers: Front line use, 1:1 torque, excellent steering and tracking, sharp vessel images, floppy and moderate support....
15mm Open Blades, 28mm Maximum Spread; Available in small(S) and large (L), in stainless steel....
Phaco Chopper, double ended; a combination of a modified MicroFinger and a pointed "quick chop" tip, in titanium...
0.5X1.5mm Tip, Oval Shape; in Titanium....
Medicine Products: